Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INHIBIT Platform: Eloctate vs Emicizumab in Hemophilia A
NCT02196207Phase 3Withdrawn
- Start
- Aug 2020
- Primary completion
- Jul 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of emicizumab in hemophilia A. Planned start Aug 2020; status: withdrawn.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT02196207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02196207.